More Than A Magazine, A Movement
Immigrant women at the Irwin County Detention Center in Georgia, with little to no knowledge of the medical procedure, were forced to undergo unwanted hysterectomies.
The United States has an ugly, and often hidden history of forced sterilization of immigrants, people of color, indigenous women, and anyone else seen as “unfit,” and therefore expendable, by the powers that be.
Despite overwhelming support for contraception, the Supreme Court opted to allow employers to single it out and makes women financially responsible for the full cost of contraception: the most fundamental part of their reproductive well-being.
As a result, contraception will be too expensive for some women to afford.
The birth control pill is already available over the counter in many countries around the world. Now, reproductive rights advocates in the U.S. are campaigning to make the pill more accessible and affordable.
The arguments of Mark Rienzi, counsel for Trump v. Pennsylvania, are dishonest, damaging and delusional. Let’s unpack each of these lies.
On Wednesday, the U.S. Supreme Court heard oral arguments in Trump v. Pennsylvania—one of the first in a slew of cases now being argued telephonically due to the COVID pandemic. The case involves the almost decade-long battle to bring to fruition the Affordable Care Act’s (ACA) promise of equitable access to essential health care for all Americans.
In a case that pits religious freedom against access to contraceptives, the Supreme Court on Wednesday will hear arguments on whether the Trump administration can make it easier for employers with religious and moral objections to opt out of providing birth control coverage in their insurance plans.
In addition to toilet paper, hand sanitizer and antibacterial wipes, COVID-19 panic purchasing is causing a shortage of pads and tampons. Faced with a shortage of options, here’s an option: Stop your period.
When the birth control pill hit the U.S. market 51 years ago, the hope had been for a male method to follow close at its heels. Yet, despite decades of research and periodic hopeful headlines, progress has been largely indiscernible. But now, researchers are touting new developments.
One year ago yesterday a district court said the FDA had “acted in bad faith and in response to political pressure” in its decision to force anyone under 17 get a prescription to purchase EC. The court ordered the FDA to look at the evidence involving age restriction again and reconsider OTC access for 17-year-olds.
